Compare RPM & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPM | NBIX |
|---|---|---|
| Founded | 1947 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | RPM | NBIX |
|---|---|---|
| Price | $110.20 | $174.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 22 |
| Target Price | $126.54 | ★ $180.91 |
| AVG Volume (30 Days) | 684.3K | ★ 1.1M |
| Earning Date | 04-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | 17.32 | ★ 41.95 |
| EPS | ★ 3.43 | 1.91 |
| Revenue | ★ $5,321,643,000.00 | $161,626,000.00 |
| Revenue This Year | $6.91 | $24.73 |
| Revenue Next Year | $5.15 | $13.14 |
| P/E Ratio | ★ $32.54 | $91.24 |
| Revenue Growth | 7.33 | ★ 977.51 |
| 52 Week Low | $92.92 | $122.14 |
| 52 Week High | $129.12 | $174.38 |
| Indicator | RPM | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 67.99 |
| Support Level | $104.29 | $153.96 |
| Resistance Level | $113.38 | N/A |
| Average True Range (ATR) | 2.52 | 4.48 |
| MACD | 0.07 | 0.66 |
| Stochastic Oscillator | 62.52 | 95.56 |
RPM International Inc manufactures and sells a variety of paints, coatings, and adhesives. The firm organizes itself into four segments based on product type. The construction products group sells coatings, roofing, insulation, and other products to distributors, contractors, and end consumers globally. The performance coatings group produces coatings that are used in construction and industrial applications like floorings and corrosion control. The consumer group sells paint, finishes, and similar products to individual consumers through hardware and craft stores. The specialty products group sells a line of products ranging from niche applications of the other groups to marine finishes, to edible food colorings. The majority of revenue is from the construction products and North America.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.